|
Market Closed -
Nasdaq
02:30:00 07/02/2026 am IST
|
5-day change
|
1st Jan Change
|
|
141.20 USD
|
+2.37%
|
 |
+3.78%
|
-0.44%
|
|
21/01 |
Neurocrine Biosciences Insider Sold Shares Worth $4,830,458, According to a Recent SEC Filing
|
MT
| |
10/12 |
Neurocrine Biosciences Insider Sold Shares Worth $698,615, According to a Recent SEC Filing
|
MT
| |
05/12 |
Neurocrine Biosciences Insider Sold Shares Worth $2,289,083, According to a Recent SEC Filing
|
MT
| |
03/12 |
Neurocrine Biosciences Insider Sold Shares Worth $905,881, According to a Recent SEC Filing
|
MT
| |
27/11 |
Neurocrine Biosciences Insider Sold Shares Worth $2,150,513, According to a Recent SEC Filing
|
MT
| |
07/25/07 |
Neurocrine Biosciences appoints Mike Sibley as senior vice president, general manager of neuropsychiatry franchise
|
RE
| |
07/25/07 |
Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
|
CI
| |
26/25/26 |
Innovent Biologics, Inc. Appoints Stephen A. Sherwin as an Independent Non-Executive Director and A Member of the Strategy Committee of the Board, Effective August 26, 2025
|
CI
| |
12/25/12 |
Neurocrine Biosciences Insider Sold Shares Worth $7,803,688, According to a Recent SEC Filing
|
MT
| |
10/25/10 |
Neurocrine Biosciences Names Lewis Choi as Chief Information Officer
|
MT
| |
10/25/10 |
Neurocrine Biosciences Appoints Lewis Choi As Chief Information Officer
|
RE
| |
10/25/10 |
Neurocrine Biosciences, Inc. Announces the Appointment of Lewis Choi as Chief Information Officer, Effective June 9, 2025
|
CI
| |
08/25/08 |
Neurocrine Biosciences Insider Sold Shares Worth $3,305,952, According to a Recent SEC Filing
|
MT
| |
04/25/04 |
Neurocrine Biosciences Appoints New Chief Medical Officer
|
MT
| |
04/25/04 |
Neurocrine Biosciences Appoints Dr. Sanjay Keswani As Chief Medical Officer
|
RE
| |
04/25/04 |
Neurocrine Biosciences Appoints Sanjay Keswani as Chief Medical Officer, Effective June 2, 2025
|
CI
| |
18/25/18 |
Neurocrine Biosciences Insider Sold Shares Worth $1,613,923, According to a Recent SEC Filing
|
MT
| |
05/25/05 |
Neurocrine Biosciences Insider Sold Shares Worth $413,967, According to a Recent SEC Filing
|
MT
| |
30/25/30 |
Neurocrine Biosciences Insider Sold Shares Worth $21,836,503, According to a Recent SEC Filing
|
MT
| |
24/25/24 |
Andrew Ratz Joins Neurocrine Biosciences, Inc. as Senior Vice President of Drug Development, Delivery and Device
|
CI
| |
18/25/18 |
Neurocrine Biosciences Insider Sold Shares Worth $9,197,550, According to a Recent SEC Filing
|
MT
| |
13/24/13 |
ATyr Pharma, Inc. Appoints Eric Benevich to Its Board of Directors
|
CI
| |
17/24/17 |
Neurocrine Biosciences Insider Sold Shares Worth $2,090,333, According to a Recent SEC Filing
|
MT
| |
16/24/16 |
Neurocrine Biosciences Insider Sold Shares Worth $1,740,450, According to a Recent SEC Filing
|
MT
| |
16/24/16 |
Neurocrine Biosciences Insider Sold Shares Worth $2,120,347, According to a Recent SEC Filing
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
